Surface Oncology, Inc. (SURF)
| Market Cap | 264.80M |
| Revenue (ttm) | 89.20M |
| Net Income (ttm) | 21.21M |
| Shares Out | 41.62M |
| EPS (ttm) | 0.53 |
| PE Ratio | 11.47 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $6.07 |
| Previous Close | $6.22 |
| Change ($) | -0.15 |
| Change (%) | -2.41% |
| Day's Open | 6.27 |
| Day's Range | 6.04 - 6.33 |
| Day's Volume | 473,421 |
| 52-Week Range | 4.87 - 14.40 |
Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
Brings 25 years of strategic leadership experience across healthcare Brings 25 years of strategic leadership experience across healthcare
Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezoliz...
Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches
CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...
It's the right time to be decisive, if you can tolerate uncertainty.
Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.
Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviron...
SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting
Henry Rath announced as chief business officer, Alison O'Neill as chief medical officer and Jessica Fees as chief financial officer Henry Rath announced as chief business officer, Alison O'Neill as chie...
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today a...
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...
The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.
Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, ...
Its pancreatic cancer drug gets a nod from the FDA.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...
Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause cer...
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.
Surface Oncology Inc (NASDAQ: SURF) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Surface's SRF388 with the latter's Keytruda (pembrolizumab). This combination ...
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 345.71% and 3.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, t...
Experienced clinical development executive to succeed current CEO Jeff Goater, who will become Chairman of the Board
These baby biotechs are itching to come out of their shells.
Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...
Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Investors reacted negatively to a big licensing deal.
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG
Biotech investors had more than just vaccines to think about this year.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...
One has a better chance to keep climbing than the other does.
These three stocks are loaded with potential, but need to be watched carefully over the next few weeks.
Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose - limiting toxicities
CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviron...
SRF388 inhibit s hepatocellular carcinoma tumor growth as a single agent in a preclinical model
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Crystal structure of IL-27 in complex with SRF388 demonstrates inhibition of downstream signaling events and provides basis to measure therapeutic inhibition of IL-27 Crystal structure of IL-27 in compl...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
The small biotech could be preparing to sell to a big drugmaker.
About SURF
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protei... [Read more...]
| Industry Biotechnology | IPO Date Apr 19, 2018 |
| CEO J. Jeffrey Goater | Employees 51 |
| Stock Exchange NASDAQ | Ticker Symbol SURF |
Analyst Forecasts
According to 5 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is 16.40, which is an increase of 170.18% from the latest price.